Balance Sheet
Cash Flow Statement
AcquisitionsAmortizationCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in TaxesDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and Equipment
Growth Metrics
Income Statement
Others
Ratios

Gsk (GLAXF) Other financing activities (2016 - 2025)

Historic Other financing activities for Gsk (GLAXF) over the last 17 years, with Q4 2025 value amounting to -$33.3 million.

  • Gsk's Other financing activities fell 13198.32% to -$33.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $62.9 million, marking a year-over-year decrease of 6160.02%. This contributed to the annual value of $60.7 million for FY2025, which is 6321.25% down from last year.
  • Per Gsk's latest filing, its Other financing activities stood at -$33.3 million for Q4 2025, which was down 13198.32% from -$64.8 million recorded in Q3 2025.
  • Gsk's 5-year Other financing activities high stood at $12.4 billion for Q1 2022, and its period low was -$253.7 million during Q3 2021.
  • In the last 5 years, Gsk's Other financing activities had a median value of $9.9 million in 2021 and averaged $1.2 billion.
  • As far as peak fluctuations go, Gsk's Other financing activities surged by 11281645.0% in 2022, and later crashed by 72297.28% in 2025.
  • Over the past 5 years, Gsk's Other financing activities (Quarter) stood at $9.4 million in 2021, then surged by 112816.45% to $10.7 billion in 2022, then crashed by 97.86% to $228.4 million in 2023, then tumbled by 54.48% to $104.0 million in 2024, then crashed by 131.98% to -$33.3 million in 2025.
  • Its last three reported values are -$33.3 million in Q4 2025, -$64.8 million for Q3 2025, and $197.4 million during Q2 2025.